Berlin, October 25, 2012 – Bayer HealthCare has entered into a strategic partnership with QIAGEN Manchester Ltd (QIAGEN) for the development of molecular in vitro companion diagnostic tests. These tests shall be used to identify patients most likely to benefit from novel anti-cancer drug candidates developed by Bayer HealthCare.

Companion diagnostic tests aim to unlock molecular information from each patient’s tumor genome to guide treatment decisions with targeted medications for cancer and other diseases. This collaboration will support Bayer HealthCare´s oncological development programs and is part of Bayer HealthCare’s personalized medicine approach.

Under the terms of the agreement Qiagen will develop, manufacture and commercialize in vitro diagnostics (IVDs) as a companion diagnostic test for novel targeted anti-cancer therapies developed by Bayer HealthCare, which are currently in early development. The parties also agreed that over a period of five years they may initiate further development projects to develop molecular diagnostic tests in support of additional targeted therapies. Financial terms of the agreement were not disclosed.

“We are very excited to partner with Qiagen to develop companion diagnostic tests for our novel anti-cancer agents,” said Prof. Andreas Busch, Head of Global Drug Discovery and Member of the Executive Committee of Bayer HealthCare. “This constitutes another significant step for Bayer HealthCare towards personalized medicine in cancer treatment as the early screening of patients for specific tumor markers helps to design more efficient clinical trials. Furthermore it increases the overall probability of therapeutic success for patients suffering from cancer.”

While much progress has been made in the treatment of cancer over the last years, there is still a need for improved diagnosis and treatment of cancer. In this context, Bayer HealthCare is committed to advancing the science of cancer, and translating this science into therapies that can help people with cancer live longer and to improve patients’ quality of life. Bayer HealthCare has established a broad network with external partners in the area of oncology and the company’s oncology portfolio demonstrates Bayer HealthCare’s commitment to improving the lives of people living with cancer.

“We are very pleased to be initiating these development programs and our partnership with Bayer HealthCare”, commented Dr. Helge Lubenow, Senior Vice President Molecular Diagnostics Business Area and Member of the Executive Committee of QIAGEN. “The collaboration combines Qiagen’s competencies in companion diagnostics with Bayer HealthCare’s drug development expertise in a joint effort to advance new targeted therapies for certain cancers that potentially help to reduce healthcare costs and – most importantly – advance the standard of care for patients.”

About QIAGEN
QIAGEN Manchester Ltd is a 100% subsidiary of QIAGEN N.V., a Netherlands holding company, which is the leading global provider of Sample & Assay Technologies that are used to transform biological materials into valuable molecular information. Sample technologies are used to isolate and process DNA, RNA and proteins from biological samples such as blood or tissue. Assay technologies are then used to make these isolated biomolecules visible and ready for interpretation. QIAGEN markets more than 500 products around the world, selling both consumable kits and automation systems to customers through four customer classes: Molecular Diagnostics (human healthcare), Applied Testing (forensics, veterinary testing and food safety), Pharma (pharmaceutical and biotechnology companies) and Academia (life sciences research). As of June 30, 2012, QIAGEN employed approximately 4,000 people in over 35 locations worldwide. Further information can be found at www.QIAGEN.com/.

About Bayer HealthCare
The Bayer Group is a global enterprise with core competencies in the fields of health care, agriculture and high-tech materials. Bayer HealthCare, a subgroup of Bayer AG with annual sales of EUR 17.2 billion (2011), is one of the world’s leading, innovative companies in the healthcare and medical products industry and is based in Leverkusen, Germany. The company combines the global activities of the Animal Health, Consumer Care, Medical Care and Pharmaceuticals divisions. Bayer HealthCare’s aim is to discover, develop, manufacture and market products that will improve human and animal health worldwide. Bayer HealthCare has a global workforce of 55,700 employees (Dec 31, 2011) and is represented in more than 100 countries.

Find more information at www.bayerpharma.com.
Follow us on Facebook: www.facebook.com/healthcare.bayer

Forward-Looking Statements
This release may contain forward-looking statements based on current assumptions and forecasts made by Bayer Group or subgroup management. Various known and unknown risks, uncertainties and other factors could lead to material differences between the actual future results, financial situation, development or performance of the company and the estimates given here. These factors include those discussed in Bayer’s public reports which are available on the Bayer website at www.bayer.com. The company assumes no liability whatsoever to update these forward-looking statements or to conform them to future events or developments.